Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRÎ±ME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRÎ±ME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Related Posts

Dell sees its backlog swell as big AI deals come through

Dell sees its backlog swell as big AI deals come through

Oil heads for first monthly drop since November as economic uncertainty weighs

Oil heads for first monthly drop since November as econ...

Social Security Administration announces ‘massive’ reorganization, ‘significant’ job cuts

Social Security Administration announces ‘massive’ reor...

Nvidia’s stock is in a funk. Earnings didn’t help, but here’s what could.

Nvidia’s stock is in a funk. Earnings didn’t help, but ...

Canada watchdog probing X's use of personal data in AI models' training

Canada watchdog probing X's use of personal data in AI ...

‘She’s not working outside the home’: My mother, 63, inherited $100,000. Is she too old to invest in the stock market?

‘She’s not working outside the home’: My mother, 63, in...